The Discovery of a Potent PARP1 Inhibitor Senaparib

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Poly(ADP-ribosyl)ation (PARP) enzymes, particularly PARP1, are crucial for DNA damage repair.
• PARP inhibitors are effective in treating cancers with homologous recombination deficiency, such as those with BRCA1/2 mutations.
• Approved PARP inhibitors target both PARP1 and PARP2, leveraging enzyme inhibition and DNA trapping mechanisms.

Purpose of the Study:

• To introduce Senaparib, a novel PARP1 inhibitor with a unique chemical structure and high potency.
• To evaluate the efficacy of Senaparib in preclinical cancer models, including those with BRCA1/2 mutations.
• To assess the synergistic effects of Senaparib in combination with temozolomide.

Main Methods:

• In vitro cell viability assays against tumor cells with BRCA1/2 mutations.
• In vivo efficacy studies using cell line-derived and patient-derived xenograft models.
• Combination studies with temozolomide to evaluate synergistic cytotoxicity.

Main Results:

• Senaparib demonstrated high potency in inhibiting PARP1/2 enzymes and high efficacy in cell viability tests against BRCA1/2-mutated tumor cells.
• Senaparib showed significant efficacy in both cell line-derived and patient-derived xenograft models of BRCA1/2-mutated tumors.
• Combination therapy with Senaparib and temozolomide exhibited strong synergistic cytotoxicity in vitro and in vivo.

Conclusions:

• Senaparib represents a novel class of potent PARP1 inhibitors with significant therapeutic potential for cancer treatment.
• Senaparib has shown promising clinical results, meeting its primary endpoint in a Phase III ovarian cancer trial.
• Senaparib's development is advancing, with a new drug application accepted for review in China.